第3代表皮生长因子受体酪氨酸激酶抑制剂药物及其专利研究

Research on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor drugs and their patents

本文重点对国内外已上市的5个第3代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)药物及其专利信息进行了专利解读,详细分析和研究了各药物在不同技术主题如化合物、晶型和/或盐型、制备工艺、药物制剂、药物组合物和/或联合给药、药物新用途、衍生物等方面的专利情况,以期为第3代EGFR-TKI的创新药或仿制药产品立项与开发以及进行新的专利挖掘、专利保护与布局提供有效的专利信息和专利文献依据。

In this paper,five third-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)which have been marketed at home and abroad and their patent information in different technical topics were unscrambled and researched.Especially,the paper focused on the patents such as product,crystalline form,salt form,process,formulation,drug combination,new use and product derivatives,in order to provide effective patent information and reference in the process of establishing and developing projects of the third-generation EGFR-TKI for innovative drugs or generic drugs,as well as new patent mining,patent protection and layout.